Related Experiment Video
Updated: Jan 15, 2026

Nerve-sparing Mid-urethral Obstruction NeMO in Female Small Rodents
Published on: April 25, 2017
A Prospective Paired Comparison Trial of Mirabegron and Anticholinergics in Patients With Low Bladder Compliance
1Department of Urology and Urological Science Institute, Yonsei University College of Medicine, Seoul, Korea.
Purpose:
Low bladder compliance (BC) poses a significant clinical challenge. Nevertheless, studies exploring pharmacological mechanisms to improve BC remain limited. We investigated the efficacy of a β3-adrenoceptor agonist, mirabegron, on BC in comparison with anticholinergics.
Methods:
This prospective single-arm paired comparison trial included 14 patients with low BC (≤20 mL/cm H2O) despite anticholinergics treatment. After a 2-week anticholinergics-washout period, patients were treated with mirabegron for 8 weeks and then returned to 8 weeks of anticholinergics. Major treatment effect was assessed with urodynamic studies performed at baseline, 8 weeks after mirabegron treatment, and 8 weeks after consecutive anticholinergics treatment (McNemar test, Paired t-test; mean [95% confidence intervals]).
Results:
Following mirabegron, 71.43% of patients exhibited a BC of >20 mL/cm H₂O, compared to 54.55% after switching back to anticholinergics (P=0.317). BC improved significantly from 12.02 (9.52-14.52) to 39.67 (21.60-57.73) mL/cm H2O after mirabegron treatment (P=0.007), but subsequently declined to 20.94 (15.78-26.10) mL/cm H₂O after reintroduction of anticholinergics (P=0.075). Maximum cystometric capacity increased from 352.21 (282.78-421.65) to 442.71 (348.95-536.48) mL after mirabegron (P=0.091), but decreased to 402.00 (315.92-488.08) mL after returning to anticholinergics (P=0.218). Notably, detrusor pressure at end-filling decreased significantly with mirabegron, from 30.50 (25.61-35.39) to 14.43 (10.79-18.06) cm H2O (P<0.001), while increasing to 20.36 (16.26-24.46) cm H2O after returning to anticholinergics (P=0.056).
Conclusion:
A β3-adrenoceptor agonist, mirabegron, was more effective than anticholinergics in improving BC. Among the two components of improved BC-increased bladder volume and reduced detrusor filling pressure-the β3-adrenoceptor agonist showed a more pronounced effect on lowering detrusor filling pressure, compared to anticholinergics. These findings suggest that β3-adrenoceptor agonists might play an important role in reducing the tension of the bladder wall by controlling detrusor muscle tone, and this may be an important target for future research.
Related Concept Videos
Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Urinary Bladder
In males, the bladder is situated in front of the rectum, while in females, it is positioned anterior to the vagina and uterus. The bladder floor contains an inverted triangular area called the trigone, defined by the two ureteric...
Cholinergic Antagonists: Pharmacokinetics
Cholinergic Antagonists: Therapeutic Uses
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal...
Drugs for Treatment of Constipation-Predominant IBS
Urinary Tract Calculi III: Medical Management

